CYBN

Cybin
CYBN

$9.17

7.13%

Market Cap: $183M

About: Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.

Employees: 50

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

8% less funds holding

Funds holding: 107 [Q1] → 98 (-9) [Q2]

31% less capital invested

Capital invested by funds: $130M [Q1] → $89.2M (-$41M) [Q2]

33.45% less ownership

Funds ownership: 76.77% [Q1] → 43.32% (-33.45%) [Q2]

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$190

1,972%

upside

Avg. target

$190

1,972%

upside

High target

$190

1,972%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 40 / 127 met price target	1,972%upside $190	Buy Reiterated	23 Aug 2024
HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 40 / 127 met price target	1,972%upside $190	Buy Reiterated	31 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about CYBN published over the past 30 days

Cybin Provides Corporate Update on Upcoming Clinical Milestones

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones. “We are making rapid advancements in our two lead clinical programs – CYB003, our proprietary deuterated psilocin program in development for the.

Cybin Provides Corporate Update on Upcoming Clinical Milestones

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Cybin's CYB003 and CYB004 programs show promising results in treating depression and anxiety, with CYB003 achieving 75% remission in Phase 2 trials. Phase 3 trials, leveraging a strong IP portfolio and a streamlined operational structure.

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Cybin Announces Completion of Previously Announced Share Consolidation

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company's issued and outstanding common shares (the “Common Shares”) on the basis of one new Common Share for every 38 existing Common Shares (the.

Cybin Announces Completion of Previously Announced Share Consolidation

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat and panel at the H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9-11, 2024 in New Y.

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on August 27, 2024 (the “Meeting”). There were 87 shareholders represented in person or.

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Inovalis Real Estate Investment Trust Provides Supplemental Information in Connection With Its Upcoming Special Meeting of Unitholders to Be Held on September 4, 2024

TORONTO--(BUSINESS WIRE)--Inovalis Real Estate Investment Trust (the “REIT”) (TSX: INO.UN) today announced that, in connection with the upcoming special meeting of unitholders of the REIT to be held on September 4, 2024 (the “Special Meeting”), the REIT is providing supplemental disclosure by way of this press release on certain matters related to action to be taken at the Special Meeting. At the Special Meeting, unitholders will be asked to consider and, if thought advisable, pass an ordinary.

Inovalis Real Estate Investment Trust Provides Supplemental Information in Connection With Its Upcoming Special Meeting of Unitholders to Be Held on September 4, 2024

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it held a Type B Initial Breakthrough Therapy Meeting with the U.S. Food and Drug Administration (“FDA”) late last week in Washington, D.C. The Company plans to initiate its Phase 3 pivotal trial of CYB003 fo.

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its first quarter ended June 30, 2024, and recent business highlights. “During the recent quarter we continued to move quickly, having achieved meaningful progress on the development.

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, taking place August 13-14, 2024 in Boston, MA. Mr. Drysdale's.

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

See News Rankings